Document is current
Any future updates will be listed below
-
Authors
Edison, Paul https://orcid.org/0000-0002-6551-2002
Femminella, Grazia Daniela
Ritchie, Craig
Nowell, Joseph
Holmes, Clive
Walker, Zuzana https://orcid.org/0000-0001-7346-8200
Ridha, Basil
Raza, Sanara
Livingston, Nicholas R.
Frangou, Eleni
Love, Sharon
Williams, Gareth
Lawrence, Robert
Mcfarlane, Brady
Archer, Hilary
Coulthard, Elizabeth
Underwood, Benjamin R. https://orcid.org/0000-0003-3427-9487
Koranteng, Paul
Karim, Salman
Bannister, Carol
Perneczky, Robert
Prasanna, Aparna
Junaid, Kehinde
McGuinness, Bernadette
Nilforooshan, Ramin https://orcid.org/0000-0001-9801-183X
Macharouthu, Ajay
Donaldson, Andrew
Thacker, Simon
Russell, Gregor
Malik, Naghma
Mate, Vandana
Knight, Lucy
Kshemendran, Sajeev
Holscher, Christian https://orcid.org/0000-0002-8159-3260
Mansouri, Anita
Chester-Jones, Mae
Holmes, Jane
Tan, Trisha https://orcid.org/0000-0001-5873-3432
Williams, Steve https://orcid.org/0000-0003-4299-1941
Ashraf, Azhaar
Brooks, David J.
Harrison, John https://orcid.org/0000-0002-0225-4923
Hinz, Rainer https://orcid.org/0000-0002-7808-9207
Tadros, George
Passmore, Anthony Peter
Ballard, Clive
-
Funding
Funding for this research was provided by:
Alzheimer’s Drug Discovery Foundation (WNCN-P40813; WNCN-P62411)
- License Information
-
More Information
Article History
Received: 17 June 2025
Accepted: 6 November 2025
First Online: 1 December 2025
Competing interests
: P.E. was funded by the Medical Research Council and now by the Higher Education Funding Council for England (HEFCE). He has also received grants from Alzheimer’s Research UK, the Alzheimer’s Drug Discovery Foundation, Alzheimer’s Society UK, Novo Nordisk, GE Healthcare, AstraZeneca, Pfizer, Eli Lilly and Piramal Life Sciences. He has received speaker fees from Novo Nordisk, Pfizer, Nordea and Piramal Life Sciences. He has received educational and research grants from GE Healthcare, Novo Nordisk, Piramal Life Sciences/Life Molecular Imaging, Avid Radiopharmaceuticals and Eli Lilly. He was an external consultant to Novo Nordisk and has participated in their Scientific Advisory Board. He is a consultant to Roche, Pfizer and Biohaven. He is the director of Edison Health Sciences Ltd and Edison Sciences Limited. He is a member of the Scientific Advisory Board of CytoDyn and holds shares in CytoDyn. J. Harrison reports receipt of personal fees in the past 2 years from Actinogen, AlzeCure, Aptinyx, AstraZeneca, Athira Pharma, Axoltis, Axon Neuroscience, Bial Biotech, Biogen Idec, Boehringer Ingelheim, Brands2Life, Cerecin, Cognito, Cognition Therapeutics, Compass Pathways, Corlieve, Curasen, EIP Pharma, Eisai, GfHEU, Heptares, Impact, Ki Elements, LSP Operations, Lundbeck, Lysosomal Therapeutics, MyCognition, Neurotrack, the National Health Service, Novartis, Novo Nordisk, Nutricia, Probiodrug, Prothena, Recognify, Regeneron, reMYND, Roche, Signant, Syndesi Therapeutics, Takeda, Vivoryon Therapeutics and Winterlight Labs. Additionally, he holds stock options in Neurotrack and is a joint holder of patents with MyCognition, Ltd. B.R.U.ʼs position is partially funded by a donation from Gnodde Goldman Sachs Giving. The other authors declare no competing interests.
